盐酸维拉佐酮(Vilazodone Hydrochloride) - 药物靶点：5-HT1A receptor x SERT_在研适应症：抑郁症，重度抑郁症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Vilazodone、Vilazodone hydrochloride (USAN)、EMD-515259

+ [4]

靶点

5-HT1A receptor x SERT

作用方式

激动剂

作用机制

5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、SERT激动剂(5-羟色胺转运体激动剂)

治疗领域

神经系统疾病

在研适应症

抑郁症重度抑郁症

非在研适应症

顺行性遗忘广泛性焦虑障碍

原研机构

Forest Laboratories, Inc.

在研机构

瑞阳制药股份有限公司

AbbVie, Inc.

Libbs Farmacêutica Ltda.

非在研机构

Forest Laboratories LLC

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2011-01-21),

重度抑郁症

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

结构/序列

分子式C26H28ClN5O2

InChIKeyRPZBRGFNBNQSOP-UHFFFAOYSA-N

CAS号163521-08-2

关联

40

项与盐酸维拉佐酮相关的临床试验

NCT05948579

/ Not yet recruiting临床2期IIT

A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members, Veterans, and Non-Veteran Civilians With PTSD

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.
Intervention B - Vilazodone will assess the safety and efficacy of vilzodone in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.

开始日期2027-08-01

申办/合作机构

Global Coalition For Adaptive Research, Inc.

[+6]

NCT05422612

/ Recruiting临床2期IIT

A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members, Veterans, and Non-Veteran Civilians With PTSD

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the available cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). The master protocol describes the default procedures and analyses for all cohorts; treatment-specific eligibility requirements, safety and efficacy procedures, or endpoints are described in the cohort-specific appendices and reflected in the intervention-specific clinicaltrials.gov records.

开始日期2023-11-02

申办/合作机构

Global Coalition For Adaptive Research, Inc.

[+6]

CTRI/2022/07/043818

/ CompletedN/AIIT

Efficacy and safety of Vilazodone versus Escitalopram versus Vortioxetine as Antidepressant in patients with major Depressive Disorder : An open-labeled randomizes study in a Tertiary care hospital

开始日期2022-07-11

申办/合作机构-

100 项与盐酸维拉佐酮相关的临床结果

登录后查看更多信息

100 项与盐酸维拉佐酮相关的转化医学

登录后查看更多信息

100 项与盐酸维拉佐酮相关的专利（医药）

登录后查看更多信息

405

项与盐酸维拉佐酮相关的文献（医药）

2026-09-01·NEUROPHARMACOLOGY

Unexpected mechanisms of repurposed drugs in the pathogenic pathways of neurodegenerative diseases. Discovering new neuroprotective therapies in cellular models

Article

作者: León, R ; Torres-Rico, M ; Pascual-Guerra, J ; Arasmou-Idrovo, M S ; García, A G ; Gironda-Martínez, A ; Marín-Rodríguez, B

Advances in biomedicine have increased life expectancy, leading to a growing prevalence of age-related neurodegenerative diseases such as Alzheimer's and Parkinson's disease, alongside disorders of genetic or environmental origin including multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis. Despite their diverse etiologies, these conditions share convergent pathogenic mechanisms-calcium overload, neuroinflammation, and oxidative stress-that drive neuronal apoptosis and progressive neurodegeneration. Developing therapies that effectively target these interconnected pathways remains a major challenge. Here, we applied a drug-repurposing pipeline integrating computational chemistry, calcium channel affinity prediction, and in vitro validation in SH-SY5Y and HEK293 cells. Eight clinically approved CNS drugs were screened for activity against Caᵥ1, Orai1, and P2X7 channels, and subsequently evaluated in neuroprotection assays. Several compounds demonstrated significant efficacy, with chlorpromazine showing broad-spectrum activity (neuroprotection, Caᵥ1.2 and P2X7 antagonism, anti-inflammatory effects), trimipramine emerging as a potent antioxidant, and vilazodone displaying synergistic neuroprotection in combination with procyclidine. These findings reveal multi-target pharmacological profiles in well-tolerated drugs not currently used for neurodegenerative indications. By highlighting both individual and combinatorial strategies, this work provides a foundation for translational studies aimed at repurposing approved agents for complex neurological disorders, with particular relevance to Parkinson's disease.

2026-04-01·ANTIVIRAL RESEARCH

Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m6A enzymatic activity

Article

作者: Xiong, Si-Dong ; Li, Xi-Ya ; Zheng, Yong-Tang ; Yang, Wen-Lan ; Luo, Rong-Hua ; Wang, Zi-Ling ; Zhang, Lu-Xi ; Zhang, Ting ; Zheng, Hong-Yi

The continuous emergence of new SARS-CoV-2 variants limits the effectiveness of current vaccines and monoclonal antibodies, highlighting the urgent need for complementary antiviral strategies. Targeting host proteins that are exploited by the virus represents a promising approach to achieve broad-spectrum inhibition. Given the recently established proviral role of METTL3-dependent RNA m⁶A modification in SARS-CoV-2 replication, we conducted a structure-based virtual screening to repurpose compounds with acceptable safety profiles. Subsequent biochemical validation identified onvansertib and vilazodone as direct METTL3 binders and potent inhibitors of its methyltransferase activity. Notably, both compounds effectively suppressed the replication of ancestral SARS-CoV-2 and Omicron BA.2 variant in vitro. Mechanistically, each compound potentially enhanced the innate antiviral response of the host and repressed the expression of viral entry-associated host factors during infection; this observation is consistent with the established proviral role of METTL3. In summary, these findings not only substantiate METTL3 as a viable antiviral target but also lay the foundation for further research on the therapeutic potential of onvansertib and vilazodone against COVID-19.

2026-04-01·BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY

Computational Drug Repositioning for Targeting Pf EMP1: Potential Therapeutics for Cerebral Malaria in Plasmodium falciparum

Article

作者: Patel, Kavita ; Bharti, Praveen Kumar ; Yadav, Ankit ; Mani, Ashutosh ; Gopikrishnan, Mohanraj ; Sharma, Rishu ; Verma, Kanika ; Mohan, Mradul

ABSTRACT:

Cerebral malaria, a severe complication form of Plasmodium falciparum infection, remains a major global health challenge with limited treatment options. The National Programme currently recommends quinine‐ and artemisinin‐based combination therapy (ACT) for the treatment of severe malaria. However, the growing resistance to these treatments highlights the urgent need for alternative therapeutic strategies. A key factor in cerebral malaria pathophysiology is P. falciparum erythrocyte membrane protein 1 ( Pf EMP1), which facilitates the sequestration of infected red blood cells in the microvasculature. Targeting Pf EMP1 represents a promising approach for therapeutic interventions. This study uses a multi‐modal computational approach to identify FDA‐approved drugs that could be repurposed to target Pf EMP1. Among the top candidate molecules are Lumacaftor, Vilazodone, Tucatinib, Lenvatinib, and Hydrocortisone Cypionate, which exhibit favorable docking energies (−9.1 to −8.3 kcal/mol) and potential oral bioavailability, as determined by receptor‐based screening and absorbed, distributed, metabolized, and eliminated (ADME) analysis. Molecular dynamics simulations confirm stable interactions between these drug molecules and Pf EMP1, supported by favorable potential energy profiles and structural stability. Additionally, protein–ligand interaction analysis identifies key residues involved in drug binding, providing insights into their molecular effectiveness. Gibbs's free energy landscape analysis further reinforces the stability of these drug–protein complexes, underscoring their potential as therapeutic agents. These findings highlight the significant role of computational approaches in drug discovery and offer valuable insights into repurposing FDA‐approved drugs for cerebral malaria treatment.

34

项与盐酸维拉佐酮相关的新闻（医药）

2026-05-29

·分析测试百科网

Carteolol,盐酸卡替洛尔,51781-21-6

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。 Carteolol MCE 国际站：Carteolol hydrochloride 品牌：MedChemExpress (MCE) 货号：HY-17495A CAS：51781-21-6 中文名称：盐酸卡替洛尔 Synonyms：盐酸卡替洛尔; OPC-1085 hydrochloride 纯度：99.96% 存储条件：4°C，密封保存，远离潮湿 *溶剂中：-80°C，6个月；-20°C，1个月（密封保存，远离潮湿）运输条件：美国大陆的室温；其他地方可能有所不同。产品活性：Carteolol hydrochloride (OPC-1085 hydrochloride) 是非选择性β肾上腺素受体阻断剂。生物活性：Carteolol hydrochloride (OPC-1085 hydrochloride) 是一种用于治疗青光眼的非选择性 β 受体阻滞剂。 IC50 和目标：β 肾上腺素能受体体外： Carteolol HCl 是一种 β-肾上腺素能拮抗剂，用作抗心律失常剂、抗心绞痛剂、抗高血压剂、和抗青光眼剂。 1 mmol/L 盐酸卡替洛尔 (P<0.05) 显着抑制 H2O2 诱导的细胞损伤并能够清除 O2 (EC50 值：48 mmol/L)。盐酸卡替洛尔对 UVB 引起的 HCEC 损伤具有保护作用，其自由基清除能力可能是这一作用的重要基础[1]。每天一次给予 1% 长效卡替洛尔的新藻酸盐制剂与每天两次给予标准 1% 卡替洛尔一样有效，在安全性方面没有显着差异。这种疗效在上午 9 点（最后一滴长效卡替洛尔后 24 小时或标准卡替洛尔滴后 12 小时）和上午 11 点（早上滴后 2 小时）得到验证。每天一次给予 1% 长效卡替洛尔的新型藻酸盐制剂是有效的，并且需要长期治疗的青光眼患者耐受性良好 [2]。 IC50 & Target：Beta adrenergic Receptor 热销产品：Insulin aspart | Phrixotoxin-1 (TFA) | Vilazodone (Hydrochloride) | INDY | Toltrazuril (sulfone) | Anagrelide (hydrochloride) | Cyclopentenyl uracil | Anethole trithione | Deoxyshikonin | O4I4 Trending products：Recombinant Proteins | Natural Products | Fluorescent Dye | PROTAC | Oligonucleotides 参考文献：[1]. Kuwahara, K., et al., Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro. Cornea, 2005. 24(2): p. 213-20.[2]. Trinquand, C., et al., [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]. J Fr Ophtalmol, 2003. 26(2): p. 131-6. 品牌介绍:• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；• 设有专业的实验中心和严格的质控、验证体系；• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；• 产品的生物活性多经各国客户实验验证；• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；• 与世界各大制药公司及知名科研机构建立了长期的合作。责任编辑：webmaster

2026-05-18

·antpedia分析测试百科网

Atacicept阿塞西普,阿塞西普,845264-92-8

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。 Atacicept | 阿塞西普 MCE 国际站：Atacicept 品牌：MedChemExpress (MCE) 货号：HY-P99446 CAS：845264-92-8 中文名称：阿塞西普 Synonyms：阿塞西普; TACI-Ig; TACI-Fc 5 纯度：99.5% 存储条件：请将产品存放在分析证书上推荐的条件下。运输条件：用干冰运输。产品活性：Atacicept (TACI-Ig) 是一种重组融合蛋白，包含 TACI 受体的细胞外配体结合部分和人 IgG 的 Fc 部分。Atacicept 通过结合 B 淋巴细胞刺激剂和增殖诱导配体抑制 B 细胞刺激。Atacicept 可用于 B 细胞自身免疫性疾病的研究。生物活性：Atacicept (TACI-Ig) 是一种重组融合蛋白，含有 TACI 受体的胞外配体结合部分和人 IgG 的 Fc 部分。 Atacicept 通过与 B 淋巴细胞刺激剂和增殖诱导配体结合来抑制 B 细胞刺激。 Atacicept 可用于 B 细胞自身免疫性疾病的研究[1][2]。体内： Atacicept（TACI-Ig；100 μg；腹腔注射；每周 3 次，持续 14 天；BALB/c 小鼠）可降低正常小鼠的成熟 B 细胞计数和血清抗体水平[1]。Atacicept (TACI-Ig) 可抑制胶原诱导性关节炎 (CIA) 小鼠模型中的疾病进展和自身抗体滴度[1]。体内：Atacicept (TACI-Ig; 100 μg; i.p.; 每周三次，共 14 天; BALB/c 小鼠) 降低正常小鼠成熟 B 细胞计数和血清抗体水平[1]。 Atacicept (100 μg; i.p.; 每周三次，共 21 天) 抑制胶原诱导性关节炎 (CIA) 小鼠模型的疾病进展和自身抗体滴度[1]。 MCE尚未独立证实这些方法的准确性。仅供参考。种属：Human 热销产品：Insulin aspart | Phrixotoxin-1 (TFA) | Vilazodone (Hydrochloride) | INDY | Toltrazuril (sulfone) | Anagrelide (hydrochloride) | Cyclopentenyl uracil | Anethole trithione | Deoxyshikonin | O4I4 Trending products：Recombinant Proteins | Natural Products | Fluorescent Dye | PROTAC | Oligonucleotides 参考文献：[1]. Gross JA, et, al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001 Aug;15(2):289-302. [2]. Gross JA, et, al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000 Apr 27;404(6781):995-9. 品牌介绍:• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；• 设有专业的实验中心和严格的质控、验证体系；• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；• 产品的生物活性多经各国客户实验验证；• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；• 与世界各大制药公司及知名科研机构建立了长期的合作。

2026-05-03

·分析测试百科网

Aviptadil,醋酸阿肽地尔,1444827-29-5

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。AviptadilMCE 国际站：Aviptadil acetate品牌：MedChemExpress (MCE)货号：HY-P0012ACAS：1444827-29-5中文名称：醋酸阿肽地尔；醋酸阿维他定Synonyms：醋酸阿肽地尔; Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)纯度：99.87%存储条件：Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)运输条件：美国大陆的室温；其他地方可能有所不同。产品活性：Aviptadil acetate 是一种模拟血管活性肠多肽 (VIP) 类似物，具有强的血管舒张 (vasodilatory) 效应。。Aviptadil acetate 诱导肺血管扩张，抑制血管 SMCs 增殖、血小板聚集。Aviptadil acetate 可用于肺纤维化、肺动脉高压 (PAH)、SARS-CoV-2 引起呼吸衰竭等的研究。生物活性：Aviptadil acetate 是一种类似物血管活性肠多肽 (VIP)，具有有效的血管扩张作用。 Aviptadil acetate 诱导肺血管舒张并抑制血管 SMC 增殖和血小板聚集。醋酸阿维他地尔可用于肺纤维化、肺动脉高压（PAH）和SARS-CoV-2引起的呼吸衰竭的研究，等[1]。体外：醋酸阿维他地尔以剂量依赖性方式抑制肺动脉平滑肌细胞 (PASMC) 的基底增殖和这些细胞中细胞内游离钙浓度的动员< sup>[3].Aviptadil acetate (1 nM-10 μM) 在 L2 细胞中对 CSE 诱导的细胞死亡产生浓度依赖性抑制。在 10 μM 时，Aviptadil acetate 降低 L2 细胞中 CSE 刺激的 MMP 活性和 caspase-3 活化[1]。Aviptadil acetate (10 nM-100 μM) 减弱脂多糖 (LPS)-大鼠肺泡巨噬细胞 (AM) 诱导 MMP-9 活性及其表达[3]。体内： Aviptadil acetate （1、3 和 10 mg/kg；静脉推注）被注射到尾静脉中。无作用剂量水平为 1 mg/kg。首次不耐受反应的剂量水平为 3 mg/kg，最低致死剂量水平为 >10 mg/kg。在 24 小时和 14 天后，雄性、雌性以及雄性和雌性组合的 Aviptadil 静脉注射 LD50 >10 mg/kg[3]。Aviptadil acetate （静脉推注）3 mg 会在给药后 15 至 30 分钟内导致所有 5 只雄性和 5 只雌性动物的运动能力略有下降、轻微共济失调和轻微呼吸困难。在 10 mg 剂量下，Aviptadil 在给药后 15 至 60 分钟显示略微降低的运动性、轻微的共济失调和轻微的呼吸困难，并在给药后 15 至 30 分钟略微降低所有雄性和雌性动物的肌张力[3] .CD1 小鼠仅鼻吸入暴露于雾化。剂量为 1546 μg/kg/day 的醋酸阿维他地尔具有良好的耐受性，并且在评估的任何参数中均未产生明显变化。在高达 3920 μg/kg/天的单剂量给药后未观察到变化。急性暴露前的不可观察不良反应水平 (NOAEL) 至少为 3920 μg/kg/天，10 天重复暴露后的 NOAEL 至少为 1546 μg/kg/天[3].体外：醋酸阿维他地尔 (1 nM-10 μM) 可对 L2 细胞中 CSE 诱导的细胞死亡产生浓度依赖性抑制。浓度为 10 μM 时，醋酸阿维他地尔可降低 L2 细胞中 CSE 刺激的 MMP 活性和 caspase-3 活化[1]。MCE 尚未独立证实这些方法的准确性。它们仅供参考。Sequence：HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2热销产品：Insulin aspart | Phrixotoxin-1 (TFA) | Vilazodone (Hydrochloride) | INDY | Toltrazuril (sulfone) | Anagrelide (hydrochloride) | Cyclopentenyl uracil | Anethole trithione | Deoxyshikonin | O4I4Trending products：Recombinant Proteins | Natural Products | Fluorescent Dye | PROTAC | Oligonucleotides参考文献：[1]. Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (COVID-AIV) [2]. Jian Hu, et al. Novel Targets of Drug Treatment for Pulmonary Hypertension. Am J Cardiovasc Drugs品牌介绍:• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；• 设有专业的实验中心和严格的质控、验证体系；• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；• 产品的生物活性多经各国客户实验验证；• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；• 与世界各大制药公司及知名科研机构建立了长期的合作。

100 项与盐酸维拉佐酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09699	盐酸维拉佐酮	N06AX24	DB06684

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
抑郁症	巴西	Libbs Farmacêutica Ltda.	2023-08-21
重度抑郁症	美国	AbbVie, Inc.	2011-01-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
广泛性焦虑障碍	临床3期	美国	Forest Laboratories LLC	2012-06-30
顺行性遗忘	临床2期	美国	Forest Laboratories LLC	2012-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01878292 (VLZ-MD-21, CTgov)	临床3期	重度抑郁症	529	Placebo (Placebo)	鏇齋遞築遞醖淵獵鏇積(鏇衊憲窪鬱憲範遞鏇膚) = 糧糧鑰簾鬱顧糧遞網廠夢範壓壓醖衊願繭築壓 (選廠憲製積顧網鬱壓艱, 0.921) 更多	-	2019-12-24
				Vilazodone (Vilazodone 15 mg)	鏇齋遞築遞醖淵獵鏇積(鏇衊憲窪鬱憲範遞鏇膚) = 鑰範淵遞廠鹹繭繭鬱網夢範壓壓醖衊願繭築壓 (選廠憲製積顧網鬱壓艱, 0.904) 更多
NCT01629966 (VLZ-MD-05, CTgov)	临床3期	广泛性焦虑障碍	680	Placebo (Placebo)	壓鬱鑰觸淵窪壓艱鏇築(窪夢膚築鹽簾築網網鹹) = 醖衊顧獵製憲艱糧獵觸衊夢鏇顧鹹壓壓膚醖餘 (糧積積糧網鹽築窪選遞, 7.93) 更多	-	2019-12-18
				Vilazodone (Vilazadone 20mg)	壓鬱鑰觸淵窪壓艱鏇築(窪夢膚築鹽簾築網網鹹) = 積壓選壓鏇鹽選構蓋鹹衊夢鏇顧鹹壓壓膚醖餘 (糧積積糧網鹽築窪選遞, 7.13) 更多
NCT01844115 (CTgov)	临床3期	广泛性焦虑障碍	415	Placebo (Placebo)	鑰構膚遞餘鏇衊壓遞淵(製鏇觸糧衊鹹獵糧鬱壓) = 網顧膚夢範築蓋夢顧簾願鬱膚鑰顧構願餘選築 (廠繭壓築鏇齋顧廠觸範, 7.41) 更多	-	2019-12-18
				Vilazodone (Vilazodone)	鑰構膚遞餘鏇衊壓遞淵(製鏇觸糧衊鹹獵糧鬱壓) = 膚壓襯夢蓋夢構壓衊積願鬱膚鑰顧構願餘選築 (廠繭壓築鏇齋顧廠觸範, 6.99) 更多
NCT01766401 (VLZ-MD-06, CTgov)	临床3期	广泛性焦虑障碍	402	Placebo (Placebo)	憲夢艱簾鹹齋網鑰繭顧(鬱壓製蓋憲廠積築積網) = 鹽憲衊鑰夢鏇鬱築範繭製淵繭範衊鑰鬱膚鬱淵 (選繭夢築鹽鏇齋鏇鹽淵, 7.37) 更多	-	2019-12-18
				Vilazadone (Vilazadone)	憲夢艱簾鹹齋網鑰繭顧(鬱壓製蓋憲廠積築積網) = 願夢選獵壓襯積選顧鏇製淵繭範衊鑰鬱膚鬱淵 (選繭夢築鹽鏇齋鏇鹽淵, 7.41) 更多
NCT02372799 (VLZ-MD-22, CTgov)	临床3期	重度抑郁症	473	Placebo (Placebo)	膚醖醖觸構鏇廠襯襯膚(網範艱憲鬱夢鹹獵鏇衊) = 鏇憲齋膚製範齋蓋鏇衊鹹範觸鹽築壓憲選網衊 (鑰齋網遞廠繭鹹構製醖, 0.983) 更多	-	2019-10-01
				Vilazodone (Vilazodone)	膚醖醖觸構鏇廠襯襯膚(網範艱憲鬱夢鹹獵鏇衊) = 構齋鏇簾衊齋糧願鏇醖鹹範觸鹽築壓憲選網衊 (鑰齋網遞廠繭鹹構製醖, 0.977) 更多
NCT02436239 (VLZ-MD-23, CTgov)	临床3期	重度抑郁症	330	Placebo+Vilazodone (Placebo/Vilazodone)	築蓋糧鹽糧築繭夢蓋糧 = 餘願鑰鏇觸餘襯鹽襯淵築製壓夢窪膚獵鏇壓廠 (衊觸鏇鹹衊鑰遞製願襯, 築襯窪製艱繭願網淵淵 ~ 廠餘積築鹽夢憲鹽築餘) 更多	-	2019-09-11
				Vilazodone (Vilazodone/Vilazodone)	築蓋糧鹽糧築繭夢蓋糧 = 範範顧構鹹選願餘顧築築製壓夢窪膚獵鏇壓廠 (衊觸鏇鹹衊鑰遞製願襯, 夢憲齋鹹顧範築鏇鬱觸 ~ 廠選願醖壓鹽衊窪憲憲) 更多
NCT01828515 (CTgov)	临床2期	顺行性遗忘	24	Vilazodone+Hydrocortisone (Vilazodone and Hydrocortisone)	餘淵鏇獵遞繭衊範憲積(遞製願膚鹹鹹積繭獵鏇) = 鑰艱選鬱觸願構齋願醖齋醖壓廠壓遞簾遞遞膚 (鹹齋艱築衊淵網淵壓艱, 12.48) 更多	-	2018-07-05
				Placebo+Hydrocortisone (Placebo and Hydrocortisone)	餘淵鏇獵遞繭衊範憲積(遞製願膚鹹鹹積繭獵鏇) = 鬱鑰餘網窪鏇築簾憲鹹齋醖壓廠壓遞簾遞遞膚 (鹹齋艱築衊淵網淵壓艱, 7.98) 更多
NCT01999920 (CTgov)	临床4期	分离性焦虑	24	Vilazodone (Vilazodone)	襯鏇遞衊構獵壓蓋顧鹽 = 淵鹽憲構鬱夢醖餘觸壓範築鹽醖觸憲鏇築鏇簾 (夢顧繭選窪觸餘夢獵膚, 顧窪遞選艱願簾顧觸製 ~ 艱鑰築觸膚糧鹽醖顧襯) 更多	-	2017-10-31
				Placebo (Placebo)	襯鏇遞衊構獵壓蓋顧鹽 = 窪襯鏇選糧遞壓糧醖獵範築鹽醖觸憲鏇築鏇簾 (夢顧繭選窪觸餘夢獵膚, 憲遞觸襯遞糧網艱鑰鬱 ~ 簾糧鹽齋齋膚衊窪鑰獵) 更多
NCT00644358 (CTgov)	临床3期	重度抑郁症	616	vilazodone	淵積窪網餘鹽衊淵廠顧 = 構襯夢齋廠選獵簾夢膚遞範夢膚襯醖壓糧窪鹹 (網顧網壓淵淵齋繭願積, 繭醖壓壓鹽膚夢願餘遞 ~ 廠獵醖觸餘簾廠糧築獵) 更多	-	2017-09-25
NCT01715519 (Pubmed) 人工标引	临床4期	抑郁症 \| 创伤后应激障碍	59	vilazodone	蓋憲積膚積艱鏇艱顧構(簾範觸鬱鬱積鏇獵鑰鹽) = No significant differences were observed between the groups 獵淵願淵淵鏇憲製壓窪 (糧醖夢壓鑰夢遞衊糧醖 ) 更多	不佳	2017-08-24
				Placebo